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LONG TERM VARICEAL SCLEROTHERAPY: IS
ENDOSCOPIC SCLEROSIS A UNIQUE THERAPEUTIC
APPROACH AND A TRUE ALTERNATIVE TO
SURGERY?
K-J. PAQUET, A. LAZAR, W. RAMBACH
Department of Surgery and Medicine, HEINZ-KALK-Hospital, D-8730
Bad Kissingen, Germany
(Received 18 September 1990)
Endoscopic sclerotherapy has been used to control acute variceal haemorrhage which persists despite
conservative therapy, prevent recurrent variceal haemorrhage in patients with a history of oesophageal
haemorrhage, and to prevent a haemorrhage in patients with oesophageal varices who never bled.
In this short paper will cover our personal experience with more than 2000 patients receiving
particularly paravariceal endoscopic sclerotherapy of bleeding esophageal varices, and especially
present the results of our prospective and controlled randomized trials (Table 1) and underline
the thesis that endoscopic sclerotherapy and surgical procedures for patients with portal
hypertension are complementary supporting measures or options.
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Table I Different groups with portal hypertension (95% cirrhotics) treated by mainly paravariceal
endoscopic sclerotherapy Group I-Group IV
Group Acute an uncontrollable variceal haemorrhage n 653
22 (Group Ia)-232 (Group Ib) 399
Group Ia: Acute variceal haemorrhage- prospective randomized controlled trial
(n 22 (43)) Jan. 1, 1980- Jan. 1983
Group Ib: Prospective evaluation
(n 232) Jan. 1, 1982- Jan. 1, 1987
Group II Elective treatment of variceal haemorrhage (n-- 1247)
Group IIIa: Prospective treatment of oesophageal varices (n 36 (72))
First prospective randomized controlled trial
(Jan. 1, 1978- Jan. 1, 1980)
Group IIIb: Prophylactic treatment of oesophageal varices (n 43 (85))
Second prospective randomized ongoing trial (Sept. 1, 1987- July 1, 1990)
Group IV Acute and elective treatment of variceal haemorrhage in babies and children (n 71)
Correspondence to: K.-J. Paquet, Department of Surgery, HEINZ-KALK-Hospital, D-8730 Bad
Kissingen, Germany12 K-J. PAQUET ET AL.
INITIAL MANAGEMENT
Emergency endoscopic sclerotherapy can be performed immediately, at the time of
the first diagnostic endoscopy, as preferred and recommended by our group or it
can be delayed until the variceal haemorrhage has been controlled by conservative
measures with or without the use of a pharmacologic agent or balloon tamponade.
The use of immediate sclerotherapy requires a high degree of skill. We recommend
its use whenever possible, since it provides instant control of haemorrhage. If these
conditions are not fullfilled, we recommend pharmacological therapy or balloon
tamponade and transfer of the patient to a specialist center.
Table 2 Results of controlled trials of emergency injection sclerotherapy of bleeding esophageal
varices
Reference No. ofpatients
Method of emergency Haemostasis Survival rate
injection sclerotherapy (immediate) after 1 year
i.v., p.v. (%) (sc/c) (%)
Paquet and Feussner 21
1985
Larson et al. 44
1986
Polidocanol 0.5 + 1% p.v.
Tetradecylsulfate 3% i.v.
90 (55) 79 (38)
85 (47) 62 (54)
CUMULATIVE
SURVIVAL
(%)
Endoscopic Sclerotherapy (22)
75
5O
25
Esophageal Tarnponade (21)
0.1
0 2
FOLLOW-UP (years)
Figure 1 Cumulative survival curve using the method of KAPLAN-MEIER for the controlled rando-
mized trial comparing the SENGSTAKEN-BLAKEMORE tube with emergency endoscopic sclerother-
apy during emergency.LONG-TERM VARICEAL SCLEROTHERAPY 13
Table 3 Aetiology of the intra- and prehepatic block of prospective evaluation of immediate endo-
scopic injection sclerosis (IES) (n 232; Jan. 1, 1982- Jan. 1, 1987)
Number Percent
A. Underlying disease
Alcoholic cirrhosis
Posthepatitic cirrhosis
Cirrhosis of unknown aetiology
Primary biliary cirrhosis
Extrahepatic bile duct atresia
Secondary biliary cirrhosis
Liver cirrhosis (total)
138 59.5
47 20.3
17 7.3
11 4.7
2 0.9
0.4
216 93.1
Prehepatic block 9 3.9
Liver fibrosis 5 2.2
Schistosomiasis 0.4
Mucoviscidosis 0.4
Non-cirrhotic patients (total) 16 6.9
B. Classification
CHILD-PUGH A* 53 23
CHILD-PUGH B 70 30
CHILD-PUGH C 109 47
Total 232 100
Non-cirrhotic patients classified CHILD-PUGH A
Blon
Figure 2 Schematic presentation of the use of the LINTON-NACHLAS tube.14 K-J. PAQUET ET AL.
After sclerotherapy has controlled the haemorrhage, we support the view that at
least two to four additional sessions are necessary to obliterate the varices by
intravariceal or combined injection or to protect them by scar tissue by paravariceal
injections. In two controlled trials one by our group it was demonstrated that
emergency injection sclerotherapy significantly improved haemostastis and survival
in comparison with other conservative measures (Table 2) 1’2
The cumulative survival curve using the method ofKAPLAN-MEIER (Figure 1)
demonstrates a statistically significant difference in favour of sclerotherapy (IEIS)
after six months (p <0.05) and a higher significance after 36 months (p <0.0005).
We prospectively treated 232 patients from January 1, 1982 to January 1, 1987 with
the following CHILD-PUGH criteria3:53 (23%) A, 70 (30%) B and 109 (47%) C.
More than 93% had liver cirrhosis, with 60% being of alcoholic origin (Table 3). If
IEIS by the free hand technique was not successful after 15 minutes a
LINTON-NACHLAS tube (Figure 2) was inserted for 6-12 hours. In cases of
10 20 30 /+0 50 60 monfhs
Figure 3 Cumulatic survival curve after immediate endoscopic injection sclerotherapy of bleeding
oesophageal varices during emergency endoscopy (in the trial surgical treatment after sclerotherapy
failure is included).LONG-TERM VARICEAL SCLEROTHERAPY 15
recurrence of haemorrhage a second emergency endoscopy and IEIS and, if this
was not successful, a gastroesophageal disconnection (look Fig. 7) was performed
directly. During the bleeding free interval CHILD-PUGH A- and -B-patients were
selected using special criteria for shunt operation. All sclerotherapy patients were
checked after 4 months and thereafter every 6, 9 and 12 months and reinjected if
necessary. Bleeding was controlled in 9370 with IEIS and in 9770 with the combination
of IEIS and LINTON-NACHLAS tube. Definite control of haemorrhage was accom-
plished in 94%. Thirty-five patients died during the first days of admission (15.1%).
The main causes of death were liver failure and variceal haemorrhage. Only 2
patients were lost to follow up. The main causes of 39 late deaths (29.87o) were liver
failure, hepatocellular cancer and haemorrhage. The calculated cumulative survival
curve using the method of KAPLAN-MEIER demonstrates a five-year life expec-
tancy of about 50% (Figure 3). As fixed in the protocol of the trial, surgery as
treatment option was included in case of persistant and/or recurrent variceal
haemorrhage in spite of effective sclerotherapy. Number, type and mortality or
surgical procedure are listed in Table 4: mortality after emergency gastroesopha-
geal disconnection (19 cases) was 31.6 and after selective and non-selective shunt
procedures, all performed within the two weeks after successful endoscopic control
of recurrent variceal haemorrhage was 11.4%.
Table 4 Number, type and mortality of surgical procedures due to persistant and/or recurrent variceal
haemorrhage in spite of effective sclerotherapy
Mortality
Number Type Number Percent
19 Gastro-oesophageal disconnection 6 31.6
according to HASSAB-PAQUET
35 Selective and non-selective shunts 4 11.4
18 Meso-caval interposition 2 11.1
16 Spleno-renal (WARREN) 2 12.5
Porto-caval (end-to-side) 0 0
54 (24%) 10 18.5
Thus, IEIS during emergency endoscopy is established as a primary therapeutic
mode to successfully control bleeding oesophageal varices. It appears to be
superior to elective sclerotherapy. In spite of that we recommend this strategy only
for a very experienced operator and endoscopist who must be available day and
night and who also has an experienced endoscopy team with at least two additional
persons to hand.
Elective Endoscopic Sclerotherapy
Although repeated injection sclerotherapy is the most widely practised long-term
treatment after variceal bleeding, it has not yet been proved to be the single most16 K-J. PAQUET ET AL.
effective form of management. Five major controlled trials (Table 5) have eva-
luated long-term endoscopic sclerotherapy for the prevention of rebleeding4-s. In
all these studies the frequency of rebleeding was reduced in sclerotherapy patients,
although in three trials the difference to the control group was only significant when
the total number of the bleeding episodes were considered rather than the number of
patients who bled. However, up to 50% of patients rebleed on chronic sclerother-
apy, although most of the rebleeding occurs before complete eradication or
protection by scar tissue of the varices has been achieved and is of minor severity.
The beneficial effect of long-term sclerotherapy on survival, as convincingly
demonstrated in the trial from the Kings College Hospital
4 in London (Figure 4)
and confirmed by our group (Tables 6, 7, 8) is nevertheless debated. Rebleeding in
the control group of one trial was routinely treated by acute sclerosis. By the end of
this trial, most control patients had received at least one session of sclerotherapy5.
Thus, similar survival in both groups is not surprising (Figure 5). The Copenhagen
Table 5 The effect of elective endoscopic sclerotherapy on the incidence of rebleeding and survival in
randomized controlled trials of patients with variceal bleeding and cirrhosis of the liver
(sc sclerotherapy; c control)*
Reference
Rebleeding Survival
No. of rate after 2 years
patients 1 year (%) (%)
(sc/c) (sc/c) (sc/c)
Westaby, MacDougall et al. 56/60
(1983)
Terblance et al. 38/37
(1983)
49/79 78/43
(significantly (significantly
different) different)
p<0.01 p<0.01
67/82
(significantly
different)
p<0.02
45/45
(no difference)
Copenhagen-ES-Trial 93/94
(1984)
31/60 78/65
(significantly (significantly
different from different after
the 40th day) 40 days)
p<0.01 p<0.05
S6derlund 54/53
(1985)
46/66 82/58
(significantly (significantly
different) different)
p<0.05 p<0.01
Korula et al. 56/60 47/71 51/35
(1985) (significantly (significantly
different) different only
p< 0.01 if urgent shunts
are excluded)
The percentages calculated by adding the number of individuals who had rebled survived, and dividing this by the total number of
patients in the studies.LONG-TERM VARICEAL SCLEROTHERAPY 17
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Figure 4 Cumulative survival curve of the controlled trial at Kings College Hospital in London
comparing elective endoscopic sderotherapy and control; bleeding in the control group was not usually
managed by endoscopic sclerotherapy4.
Table 6 Estimated natural history after variceal bleeding in patients with liver cirrhosis according to
CHILD’s classification [from GRAHAM and LACEY-SMITHI and BURROUGHS et al. 1]
Survival rate after
Child classification 1 month 1 year 2 years
A 85 76 65
B 75 52 39
C 65 35 23
Table 7 Survival following prospective paravariceal injection sclerotherapy of 200 consecutive patients
according to CHILD’s classification
1
Survival
Classification No. ofpatients 1 year 2 years
Child A 45 99 95
Child B 60 79 78
Child C 95 62 5318
a 40-
K-J. PAQUET ET AL.
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Figure 5 Cumulative survival in the controlled trial of TERBLANCHE et al. comparing elective
endoscopic sclerotherapy (----) and controls (- -); bleeding and controls were managed by
emergency endoscopic sclerotherapy.
Table $ Rebleeding and survival in controlled randomized trial comparing sclerotherapy (ES) to shunt
operation (SO)
Author shunt
No. of
patients
ES
Time of
two years
Rebleeding survival
SO ES SO ES SO
% %
Warren et al. 1986
Rikkers et al. 1987
Cello et al. 1987
Teres et al. 1987
spleno-renal
shunt
spleno-renal
porto-caval
(CHILD C)
"so-called"
spleno-renal
shunt
36
30
32
55
35 53 3 84( + 31 59
surgery)
27 57 19 61 65 ns
32 41 16 50 44 ns
57 32.5 14.3 68 71 nsLONG-TERM VARICEAL SCLEROTHERAPY 19
trial reviewed improved survival under long-term sclerotherapy after 40 days of the
initial bleeding episodes7. Our group has compared the estimated natural history of
variceal bleeding in patients with cirrhosis according to CHILD-PUGH classifica-
tion, as shown in Table 6 with the life expectancy of 200 consecutive cirrhotics with
bleeding esophageal varices treated by endoscopic sclerotherapy prospectively9. By
this treatment option life expectancy could be prolonged in CHILD A-patients
from 65 to 95%, in CHILD B-patients from 39 to 78% and in CHILD C-patients
from 23 to 53 7o (Table 8).
However, rebleeding during initial and long-term injection sclerotherapy occurs
in 23 to 55% and remains a problem, even if it is of minor intensity. Therefore, a
surgical approach to the so-called "sclerotherapy failures" has been discussed and
recently investigated in controlled randomized trials. These randomized studies
showed contradictory results (Table 8): recurrence of haemorrhage could be
significantly prevented by elective or urgent shunt operation, but survival was only
improved in one study, when sclerotherapy failure were backed up by early surgical
treatment (Figure 6).
0.7
0 0.6
0 0.5
p<O.01
TOTAL DEAD ALIVE
36 5 31 0 Sclerosis
35 14 21 Shunt
Surgery
DSRS
L
0 6 12 18 24 30 36 42 48 54
Months
Figure 6 Preliminary results of the controlled trial of the WARREN-group comparing elective
endoscopic sclerotherapy to elective distal splenorenal shunt operation; about 30% of the sclerotherapy
group moved to the shunt group because of recurrences of haemorrhage and were declared as "failure".20 K-J. PAQUET ET AL.
Since 1975 our group has practised a specific surgical approach in the "long-term
sclerotherapy failures". This strategy is based on a definition of sclerotherapy
failures and special selection of patients for elective shunt procedures. "Sclerother-
apy failure" is defined as either at least two early or late recurrences of oesophageal
variceal bleeding during the course of endoscopic sclerotherapy, one recurrent
haemorrhage from gastric varices or recurrent bleeding from esophageal ulcers as
a sequelae of balloon tamponade and/or endoscopic sclerotherapy.
Surgical Strategy and Selection
In patients belonging to CHILD-PUGH classification C with uncontrollable recur-
rent variceal haemorrhage an emergency gastroesophageal disconnection (with or
without splenectomy or fundoplication) is performed according to
HASSAB-PAQUET (Figure 7). In a few cases with portal pressure over 40cm H20
an emergent or urgent narrow lumen meso-caval shunt is carried out.
2 3
Figure 7 Gastro-oesophageal disconnection according to HASSAB-PAQUET: devascularisation of the
upper two thirds of the stomach and 6cm of the abdominal oesophagus, separation of all connections to
the retroperitoneum and the diaphragm and selective proximal vagotomy.LONG-TERM VARICEAL SCLEROTHERAPY 21
CHILD-PUGH A- and -B-patients are considered for an elective shunt ope-
ration according to the criteria listed in Table 10: sonographic volume of the liver
should be between 1000 and 2500ml. Portal perfusion rate is measured by
sequential scintigraphy; if it is more than 30%, the patient is considered for distal
splenorenal shunt. If portal perfusion rate is between 10 and 30%, the patient is
considered for a non-selective shunt. The preferred non-selective shunt is the
narrow lumen meso-caval interposition shunt (NLMS: 10-12mm ring enforced
PTFE-prothesis). Coeliac angiography should exclude stenosis of the hepatic artery
and/or coeliac axis as well as "portal pseudoperfusion". Liver biopsy performed at
laparoscopy should not show activity of the liver disease.
Table 9 Selection criteria for elective narrow lumen mesocaval shunt interposition (NLMS) or a distal
splenorenal shunt (DSRS) in cirrhotics with recurrence of haemorrhage from oesophago-gastric varices
1. Liver volume, sonographically determined as 1000-2500 ml
2. Portal perfusion 10-30% at sequential scintigraphy
3. No activity or progression of cirrhosis seen at laparoscopy and biopsy
4. No stenosis of the hepatic arterial circulation, and suitable lumen and length of the splenic vein,
found at angiographic studies
Table 10 Number and classification of 692 consecutive patients admitted to the
HEINZ-KALK-Hospital because of bleeding from oesophagogastric varices and modality of therapy
(Jan. 1, 1982- Jan. 1, 1989)
692 patients
14
311
26
5
exclusions (2%)
CHILD-PUGH C (45%) long-term endoscopic sclerotherapy
emergent gastroesophageal disconnection according to HASSAB-PAQUET 8.5%
emergent narrow-lumen mesocaval interposition shunts (1.5%)
367 CHILD-PUGH A + B
181 CHILD-PUGH A (26%)
185 CHILD-PUGH B (27%)
MATERIAL AND RESULTS
From January 1, 1982 to January 1, 1989, 692 consecutive patients were admitted to
the HEINZ-KALK-Hospital with bleeding oesophageal varices (Table 10).
Fourteen patients had to be excluded from the prospective evaluation because of
uncontrollable haemorrhage during the first 12 to 24 hrs, or refusal of treatment. In
311 CHILD-PUGH C-patients long-term injection sclerotherapy was performed;
26 of them needed an emergency gastroesophageal disconnection because of
uncontrollable or early recurrent haemorrhage, and in 5 an NLMS. In the
remaining 367 patients- 182 of them were CHILD-PUGH A and 185 B
endoscopic scleratherapy was successful in 194. In 173 patients, with at least two22 K-J. PAQUET ET AL.
rebleedings despite long term sclerotherapy, specific selection criteria were used to
assess suitability for shunt. Eighty five patients refused shunt operation or did not
fulfill selection criteria: in this group endoscopic sclerotherapy was continued.
Eighty-eight patients were shunted (Table 11): 54 narrow lumen mesocaval 32
distal spleno-renal shunts, 1 porto-caval and one spleno-renal LINTON-shunt. The
continued sclerotherapy and shunt groups were comparable concerning number,
demographic characteristics, aetiology, severity and histology of liver disease
(Table 12). There was no significant difference of mortality at 30 days (5 vs. 7%).
Twenty nine patients from the surviving 81 receiving continued sclerotherapy
(36%) died during the later follow up. Mean follow-up time in both groups was 43
months. Four patients of endoscopic sclerotherapy and 3 of the shunt-group were
lost to follow-up after 18 to 39 months. Seventeen shunt-patients died during the
late follow-up (18%). The cumulative survival curves, calculated using the method
of KAPLAN-MEIER are shown in Figure 8. The two curves are significantly (p<
0.01) different in favour of patients selected for shunt after sclerotherapy had
failed.
Table 11 Modalities of therapy in 367 patients with CHILD-PUGH A- and -B-classification and types
of shunts performed
367 patients (CHILD-PUGH A + B)
194 long-term endoscopic injection sclerotherapy
173 patients with at least two rebleedings despite effective long-term endoscopic sclerotherapy
85 patients (shunt refused (69) or selection criteria not fullfilled (26))
88 patients were shunted
54 narrow-lumen meso-caval interposition shunt (NLMS)
32 distal spleno-renal shunt (DSRS)
porto-caval shunt
proximal spleno-renal shunt (LINTON)
Table 12 Demographic characteristics, aetiology, severity and histology of the liver disease, early and
long-term results in 173 patients, either selected for endoscopic sclerotherapy or shunt operation
Endoscopic Shunt
sclerosis operation
Number of patients 85 88
CHILD-PUGH A 41 (48%) 40 (46%)
CHILD-PUGH B 44 (52%) 48 (55’)o)
alcoholic cirrhosis 57 (67’)’0) 57 (65%)
posthepatitic cirrhosis 19 (22%) 20 (22%)
other types of cirrhosis 9 (11%) 11 (13%)
mortality at 30 days 4 (5%) 6 (7%)
late mortality
(up to Jan. 1, 1989) 29 (36’)’o) 14 (17%)
(p<O.O)LONG-TERM VARICEAL SCLEROTHERAPY 23
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Figure 8 Cumulative survival curve according KAPLAN-MEIER comparing elective endoscopic
sclerotherapy to elective narrow-lumen mesocaval or distal splenorenal shunt in a prospective study
(Broken line shunt).
Conclusions
The art of managing patients with current variceal bleeding during continued
endoscopic sclerotherapy is to balance the risk of hepatic failure and recurrent
bleeding. Today endoscopic sclerotherapy is the best first line of treatment, and is
more effective than conservative therapy alone, in preventing rebleeding and
improving survival. Endoscopic sclerotherapy does not change total liver perfusion,
portal perfusion and thus liver function. On the other hand, in spite of long-term
and effective sclerotherapy at least 30% of early and late rebleeders should be
expected, with the risk of liver failure induced by rebleeding. Acute rebleeders are
best managed by devascularisation procedures and rarely by emergency shunt
operations in spite of the fact that it is questioned that this strategy instead of
chronic sclerotherapy can improve survival. Those patients who rebleed need
urgent and effective therapy. In chronic rebleeders selective distal splenorenal
shunt and non-selective narrow-lumen meso-caval shunts can prevent early and late
rebleeding without negative influence on liver haemodynamics and hepatic function
in CHILD-PUGH A- and -B-patients. Furthermore these shunts are able to24 K-J. PAQUET ET AL.
prolong survival without deteriation of liver function or a higher frequency of liver
failure on long term basis. Our trial demonstrates for the first time that this is
particularly true for CHILD-PUGH A- and -B-patients who fulfill special selection
criteria. Furthermore non-selective narrow lumen meso-caval interposition shunt
has been proved to be a good alternative to selective distal splenorenal
Warren-shunt if this is technically impossible or haemodynamically not advisable.
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